KEY TAKEAWAYS
- The PLATON trial aimed to improve personalized medicine by connecting scientists and pts to share clinical and molecular profiles, recruit new pts for clinical trials, and access a biobank.
- The study enrolls pts during or before first-line treatment and collects information on routine clinical data, molecular testing, and tumor response.
- The study found that PLATON is a feasible and valuable resource for personalized medicine research.
Personalized medicine in oncology is promising but needs improvement in profiling, applicability, and accessibility. PLATON is an interactive network connecting scientists and patients(pts) to improve personalized medicine.
Researchers aimed to improve personalized medicine by connecting scientists and patients to share clinical and molecular profiles, recruit new patients for clinical trials, and access a biobank.
The study enrolls pts during or before first-line treatment and collects routine clinical data (baseline data, histopathology reports, treatment decisions, etc.). All anti-tumor therapy lines, tumor response, survival, and quality of life data are recorded during follow-up. PLATON offers molecular testing (Foundation CDx and CDx Liquid) and provides reports and molecular pathology case discussions by its board of pathology experts. The study also enrolls cases with compatible external NGS reports through an evaluation by the central review board of medical advisors. PLATON is conducted by the Institute of Clinical Cancer Research (IKF) in Frankfurt.
The study included 188 pts (122 male and 66 female) up to date with comprehensive NGS report data and clinical information from 31 sites. The average age is 65 for males and 67 for females, ranging from 21 to 88 for males and 24 to 87 for females. Diagnostic cohorts include 43 esophagogastric cancer cases, 50 intra-/extrahepatic cholangiocellular carcinoma cases, 13 gallbladder carcinoma cases, 35 hepatocellular cancer cases, and 47 pancreatic cancer cases. Among these, 88 pts are still under observation, while 87 have unfortunately passed away within 10 to 726 days of recruitment. In 134 cases, the PLATON project’s “Molecular Pathology Case Discussion” addressed their conditions, with 87 pts receiving targeted therapies based on their molecular tumor profiles. About 2,707 genetic alterations were identified, with 1,640 being variants of unknown significance (VUS). Tumor mutational burden (TMB) ranged from over 10 to 67 mutations per megabase and was detected in 21 cases.
The study found that PLATON is a feasible and valuable resource for personalized medicine research.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e15097?af=R
Clinical Trial: https://clinicaltrials.gov/study/NCT05489250
Arndt Vogel, Thorsten Götze, Anna Lena Saborowski, Nihat Bugra Agaoglu, Anke C. Reinacher-Schick, Benedikt Westphalen, Peter Wild, Alexander Stein, Claudia Pauligk, Bianca Zäpf, and Salah-Eddin Al-Batran. DOI: 10.1200/JCO.2023.41.16_suppl.e15097 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e15097-e15097.
